What is CORE Diagnostics?
CORE Diagnostics operates as a premier diagnostic center and pathology laboratory, specializing in complex medical testing. The company provides a comprehensive suite of services, including molecular biology, immunohistochemistry, and cytopathology, which are critical for the diagnosis of cancer, inherited diseases, and reproductive health conditions. By integrating cutting-edge diagnostic technologies, the firm serves as a vital partner to healthcare professionals and patients alike, ensuring that clinical decisions are backed by precise and reliable data. Its market position is characterized by a focus on high-end diagnostics that require significant technical expertise and infrastructure, distinguishing it from standard laboratory service providers.
How much funding has CORE Diagnostics raised?
CORE Diagnostics has raised a total of $17.3M across 2 funding rounds:
Series A
$5M
Series B
$12.3M
Series A (2012): $5M with participation from Artiman Ventures
Series B (2016): $12.3M led by F-Prime Capital Partners, Eight Roads Ventures, and Artiman Ventures
Key Investors in CORE Diagnostics
F-Prime Capital Partners
A global venture capital firm with a deep focus on healthcare and technology, leveraging a team of scientists and clinicians to support transformative medical companies.
Eight Roads Ventures
A global proprietary investment firm backed by Fidelity, specializing in scaling high-growth companies across the healthcare and technology sectors.
Artiman Ventures
An investment firm focused on innovative, early-to-growth stage companies that leverage technology to disrupt sectors including healthcare and diagnostics.
What's next for CORE Diagnostics?
With the recent influx of capital, CORE Diagnostics is well-positioned to accelerate its strategic roadmap, which likely includes the expansion of its laboratory network and the integration of next-generation sequencing capabilities. The company's focus on high-end diagnostics suggests a future trajectory centered on deepening its penetration into specialized medical markets, such as oncology and genetic screening. By maintaining its focus on technological superiority and clinical accuracy, the firm is poised to capitalize on the growing demand for sophisticated diagnostic solutions. Future growth will likely be driven by continued investment in R&D and the scaling of its operational footprint to meet the increasing complexity of modern healthcare requirements.
See full CORE Diagnostics company page
